Gecko-like dry adhesives have been around since about 2001 have been, but there was a big challenge for this technology for medical applications given the strict design criteria required to adjust. For use in the body, they must be adapted to adhere to a moist environment formed formed of materials adapted for medical applications. Such materials must be biocompatible, that is they do not cause inflammation; biodegradable, ie, they dissolve over time, without toxic substances, and elastic, bandage they correspond to and stretch with the body’s tissues read more . The MIT researchers met these requirements by building their medical adhesive with a biorubber by Karp, Langer and others invented. With microstructuring technology uses the same technology to computer chips, researchers impressed the biorubber build in different hill and valley profiles at nanoscale dimensions. After testing them on intestinal tissue taken from pigs, they selected the stickiest profile, one with pillars spaced just wide enough to grip and interlock with the underlying tissue.
‘This is an exciting example how nanostructures can be controlled, and it used to create a new family of adhesives, ‘ Langer said.###Other MIT authors of the paper are co – first authors Alborz Mahdavi, a former MIT lab technician now at the California Institute of Technology, Lino Ferreira, a former MIT postdoctoral fellow now at the University of Coimbra, Portugal; Jason W. Nichol and Edwin P. HST postdoctoral fellow, David JD Carter and Jeff Borenstein of Draper Laboratory; HST graduate student Chris Bettinger and MIT students Siamrut Patanavanich, Loice Chignozha, Alex Galakatos and Seungpyo Hong, all from the Department of Chemical Engineering. Other authors are from Massachusetts General Hospital and the University of Basel, Switzerland.
Sartore be noted that in prior studies when AF – MSCs in the porcine model of myocardial ischemia it vascular cells of were turned, but no at cardiomyocytes were transplanted. Nerve assist more accrual of the emerging role the bone marrow in the cardiac cell therapy, not only as a regenerative resources, but also supporting for other cells and tissues, said Amit N. Manager of the cardio regenerative medical and associate professor of surgery at University of Utah School of Medicine, and a section of editor for Cell Transplantation.
The first survey found that implantation of adult cardiomyocytes in combination with BMCs is two advantages over replanting cardiac myocytes own. First, while heart function has been obtained performed by implanting cardiomyocyte alone, the therapeutic effects of the grafting they were improved together with bone marrow cells. Second, in programmed cell death of the host cardiomyocytes has been reduced after implantation BMC only or combined with cardiomyocytes, when compared with the results after implantation cardiomyocytes alone.